Measuring PSA forms may lower number of biopsies

Baltimore-For patients with total PSA levels in the range of 2.5 to 4.0 ng/mL, measuring the proportion of precursor forms of PSA (pPSA) relative to free PSA (fPSA) may significantly lower the number of unnecessary biopsies compared with measuring percent-free PSA (%fPSA) alone, a new study suggests.

Related Videos

Related Content

Advertisement

April 30th 2025

TAR-200 boasts impressive DFS rates in papillary disease-only NMIBC

Hannah Clarke

Data showed a disease-free survival rate of 85.3% at 6 months and 81.1% at 9 months.

April 29th 2025

Pearls & Perspectives: Advancing sexual health in urology, with Rachel Rubin, MD, at AUA 2025

Amy M. Pearlman, MD Rachel Rubin, MD

Rachel Rubin, MD, discusses advancements in sexual health education and guidelines at the AUA meeting.

April 29th 2025

Advancing Patient Care: Innovations in Bladder Cancer

Sponsored by Pfizer

April 29th 2025

Pearls & Perspectives: Innovation in male fertility care with Larry Lipshultz, MD, at AUA 2025

Amy M. Pearlman, MD Larry Lipshultz, MD

Discover groundbreaking insights in urology as Larry Lipshultz, MD, shares innovative research and strategies for male fertility challenges.

April 28th 2025

Investigational ProVee System impresses in phase 3 trial in BPH

Benjamin P. Saylor

No device- or procedure-related serious AEs were observed through 12 months across the entire study population

April 28th 2025

ARANOTE substudy highlights benefits of darolutamide in Black men

Benjamin P. Saylor

The investigators reported that treatment with darolutamide reduced the risk of radiological progression or death by 49% in Black men.

Related Content

Advertisement

April 30th 2025

TAR-200 boasts impressive DFS rates in papillary disease-only NMIBC

Hannah Clarke

Data showed a disease-free survival rate of 85.3% at 6 months and 81.1% at 9 months.

April 29th 2025

Pearls & Perspectives: Advancing sexual health in urology, with Rachel Rubin, MD, at AUA 2025

Amy M. Pearlman, MD Rachel Rubin, MD

Rachel Rubin, MD, discusses advancements in sexual health education and guidelines at the AUA meeting.

April 29th 2025

Advancing Patient Care: Innovations in Bladder Cancer

Sponsored by Pfizer

April 29th 2025

Pearls & Perspectives: Innovation in male fertility care with Larry Lipshultz, MD, at AUA 2025

Amy M. Pearlman, MD Larry Lipshultz, MD

Discover groundbreaking insights in urology as Larry Lipshultz, MD, shares innovative research and strategies for male fertility challenges.

April 28th 2025

Investigational ProVee System impresses in phase 3 trial in BPH

Benjamin P. Saylor

No device- or procedure-related serious AEs were observed through 12 months across the entire study population

April 28th 2025

ARANOTE substudy highlights benefits of darolutamide in Black men

Benjamin P. Saylor

The investigators reported that treatment with darolutamide reduced the risk of radiological progression or death by 49% in Black men.